✦ LIBER ✦

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

✍ Scribed by Shanti Natarajan-Amé; Sophie Park; Lionel Ades; Norbert Vey; Agnès Guerci-Bresler; Jean-Yves Cahn; Gabriel Etienne; Dominique Bordessoule; Christophe Ravoet; Laurence Legros; Stephane Cheze; Aspasia Stamatoullas; Elisabeth Berger; Aline Schmidt; Aude Charbonnier; Marie-Pierre Chaury; Thorsten Braun; Pierre Fenaux; Francois Dreyfus; on behalf of the Groupe Francophone des Myélodysplasies (GFM)

Book ID: 114714730
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 107 KB
Volume: 158
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2012.09153.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of combination human reco

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study

✍ John M. Bennett; Mary S. Young; Jane L. Liesveld; Elisabeth Paietta; Kenneth B. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

A non-randomised dose-escalating phase I

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

✍ Didier Bouscary; Laurence Legros; Micheline Tulliez; Stéphanie Dubois; Béatrice 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB

Imatinib plus low-dose doxorubicin in pa

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib : A phase I-II study by the Spanish group for research on sarcomas

✍ Joan Maurel; Ana Sofia Martins; Andrés Poveda; José Antonio López-Guerrero; Rica 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB 👁 3 views

A Novel High Dose Chemotherapy Strategy

A Novel High Dose Chemotherapy Strategy With Bendamustine in Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients

✍ G. Visani; L. Malerba; P.M. Stefani; S. Capria; P. Galieni; F. Gaudio; G. Specch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

(F7) Randomized phase II study with GM-C

(F7) Randomized phase II study with GM-CSF and low-dose ARAC in patients with “high risk” myelodysplastic syndromes : H. Gerhartz∗, R. Marcus, A. Delmer, H. Zwierzina, T. de Witte, A. Jacobs, G. Visani, D. Fiére, P. Sonneveld, B. Labar, A.V. Hoffbrand, P. Fenaux, M. Hayat, A. Thyss, L. Debucher, B. Coiffier, W. Sizoo, R. Willemze, M. Ribeiro, S. Suciu, G. Solbu, A. Stern, R. Zittoun for the EORTC Leukemia Group. Med. Dept. III, Klinikum Groβhadern, Munich Univ., 8000 Munich 70, FRG

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 142 KB